血清中miR-155与乳腺癌的相关性

目的分析血清中miR-155的表达水平，探讨其与乳腺癌临床病理特征之间的关系。方法收集2010年12月至2011年4月入院的67例女性患者（乳腺癌45例，非乳腺癌22例）的血液标本，分离血清并提取miRNA，通过荧光实时定量PCR法检测血清中miR-155的表达水平，分析其与乳腺癌临床病理特征间的相关性。结果乳腺癌患者相比非乳腺癌患者，腋窝淋巴结转移阳性乳腺癌患者相比阴性患者血清中miR-155表达水平均上调（均P〈0．05）；在乳腺癌患者中，肿瘤大小为T1的相比T2和r乃患者，I、Ⅱ期相比Ⅲ期患者，ER、PR阳性相比阴性患者血清中的miR-155表达水平均下调（均P〈0．05）。结论血清中miR．155的表达水平与乳腺癌及其临床病理特征密切相关。miR-155可成为新-代的乳腺癌标志物，并为乳腺癌发病机制及治疗和预后判断研究提供-个新方向。

Circulating miR-155 in serum of patients with breast cancer

Objective To investigate the expression of miR-155 in serum of patients with breast cancer and explore the possibility of miR-155 in serum as a marker of beast cancer. Methods 67 cases （ breast cancer 45 cases, non-breast cancer 22 cases） were enrolled from December 2010 to April 2011. The expression level of miR-155 in serum were measured by real-time quantitative polymerase chain reaction（ real-time qPCR）analysis. The relationships between the expression level of miR-155 in serum and the feature of clinical pathology were an- alyzed. Results Compared with non-breast cancer, the expression level of miR-155 in serum of patients with breast cancer was up-regulated, The expression level of miR-155 was up-regulated in lymph positive breast cancer group compared with lymph negative breast cancer, The expression level of miR-155 was down-regulated in stage I and stage ]] breast cancer group compared with stage Ill breast cancer, The expression level of miR- 155 was down-regulated in serum of patients with ER and PR positive breast cancer compared with ER and PR negative breast cancer（P 〈 0.05）. Conclusions This study demonstrates that the expression of miR-155 have a relationship with clinical pathological feature of patient with breast cancer and can be used as a potential tumor marker of breast cancer.